title: How do abacavir and efavirenz differ in pharmacokinetics and toxicity?
authors.affiliation: Xavier University of Louisiana, HIV Outpatient Program (HOP), Medical Center of Louisiana at New Orleans, USA.
authors.forename: J
authors.initials: J
authors.lastname: Edmunds-Ogbuokiri
mesh_terms: D000328:Adult; D000480:Alkynes; D019540:Area Under Curve; D048588:Benzoxazines; D001682:Biological Availability; D000075202:Contraindications; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000009:adverse effects* / Q000493:pharmacokinetics*; D004342:Drug Hypersensitivity; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D010078:Oxazines / Q000009:adverse effects* / Q000493:pharmacokinetics*; D010353:Patient Education as Topic; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics*; D014481:United States; D000099227:Abacavir
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C098320:efavirenz